4//SEC Filing
GKCC, LLC 4
Accession 0001140361-24-037346
CIK 0001601485other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:41 PM ET
Size
7.7 KB
Accession
0001140361-24-037346
Insider Transaction Report
Form 4
Chudnovsky Yekaterina
Director10% Owner
Transactions
- Purchase
Convertible Note (convertible into Common Stock)
2024-08-12$5.81/sh+3,442,341$20,000,001→ 3,442,341 total(indirect: By LLC)Exercise: $5.81→ Common Stock (3,442,341 underlying)
GKCC, LLC
10% Owner
Transactions
- Purchase
Convertible Note (convertible into Common Stock)
2024-08-12$5.81/sh+3,442,341$20,000,001→ 3,442,341 total(indirect: By LLC)Exercise: $5.81→ Common Stock (3,442,341 underlying)
Footnotes (3)
- [F1]On August 12, 2024, GKCC, LLC (the "Purchaser") purchased from the Issuer a convertible note with an aggregate principal amount of $20,000,000 (the "Convertible Note"). The Convertible Note is convertible into shares of common stock of the Issuer at a conversion price of $5.81 per share, subject to adjustment in certain circumstances. Therefore, the Convertible Note is initially convertible into approximately 3,442,341 shares of common stock of the Issuer.
- [F2]The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum.
- [F3]Yekaterina (Katie) Chudnovsky is the sole member and manager of the Purchaser and may be deemed to beneficially own the shares held by the Purchaser.
Documents
Issuer
Elicio Therapeutics, Inc.
CIK 0001601485
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001977769
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 4:41 PM ET
- Size
- 7.7 KB